In one systematic review, 17 adult ALL patients receiving an allo-HCT following treatment with a CD19 CAR experienced improvement in event-free survival compared to the patients in CR who did not receive an allo-HCT [64]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.